semaglutide patents Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Looming GLP-1 drug patent expirations

We have created a successful regimen that includes nutrition counseling, exercise recommendations, a fiber-matrix drink, B12 shots, and appropriate prescription medications to support an achievable, sustainable weight-loss plan for you

503A Compounding Pharmacies and Evolocumab in Maine Maine-licensed 503A compounding pharmacies can prepare patient-specific evolocumab formulations when a prescribing clinician writes a valid prescription

The move will save Boston nearly $11 million, the Wu administration said in March

The acetylation of Sox13 reduces its expression at the mRNA level, subsequently decreasing the production of IL-17A, and ultimately enhancing the anti-tumor effect of ILC3 in the liver (Fig

GLP-1 Rebound Prevention: How to Keep the Weight Off After the Needle Worried about weight regain after stopping GLP-1s like Ozempic or Wegovy